Larissa Schneider

Executive Director of Pharmaceuticals, Co-founder of Rare Disease Drug Research
New York, New York, United States

Professional Overview

Larissa Schneider is an accomplished pharmaceutical executive with a proven track record of driving innovation and delivering tangible results. As the Executive Director of Pharmaceuticals and Co-founder of Rare Disease Drug Research at Johnson & Johnson, she leverages her deep industry expertise and technical acumen to lead strategic initiatives that advance the company's drug development capabilities and improve patient outcomes.

Experience Summary

Current Role

As the Executive Director of Pharmaceuticals, Larissa oversees a diverse portfolio of pharmaceutical projects, managing cross-functional teams and spearheading the development of novel therapeutic solutions. In her role as Co-founder of Rare Disease Drug Research, she has established a research program dedicated to addressing the unique challenges associated with rare disease drug development, fostering collaborations and driving breakthroughs in this critical area.

Career Progression

Larissa joined Johnson & Johnson in 2014 as an Intern Assistant, where she demonstrated her aptitude for problem-solving and innovation. She quickly rose through the ranks, assuming the position of R&D Engineer in 2015 and contributing to the successful completion of several high-profile projects. Larissa's exceptional performance and strategic thinking earned her the promotion to her current role as Executive Director of Pharmaceuticals in 2021, where she continues to make a significant impact on the company's pharmaceutical operations.

Academic Background

Larissa holds a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology, where she graduated with honors. Her academic achievements and technical expertise have been instrumental in shaping her successful career in the pharmaceutical industry.

Areas of Expertise

Larissa's areas of expertise include pharmaceutical research and development, project management, strategic planning, and team leadership. She possesses a deep understanding of the regulatory landscape, market trends, and emerging technologies that drive innovation in the industry. Her ability to collaborate cross-functionally and effectively communicate complex technical information has been pivotal in her success.

Professional Impact

Under Larissa's leadership, the Rare Disease Drug Research program has made significant strides in advancing the development of novel therapies for rare and orphan diseases. Her team's work has resulted in the successful launch of two new drug candidates, positively impacting the lives of patients and their families. Larissa's contributions have been recognized within the industry, and she is frequently invited to speak at conferences and industry events, sharing her insights and best practices with her peers.

Conclusion

Larissa Schneider's exceptional career trajectory, coupled with her unwavering commitment to innovation and patient-centric approach, positions her as a respected leader in the pharmaceutical industry. As she continues to spearhead critical initiatives at Johnson & Johnson, Larissa's expertise and strategic vision will undoubtedly drive the company's ongoing success and solidify its reputation as a premier pharmaceutical innovator.